Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Table 3 Changes in blood lipid profiles between the tenofovir amibufenamide and tenofovir alafenamide groups

	TMF group (n = 106)	TAF group (n = 109)	P value
Triglycerides (mmol/L)
Before treatment	1.57 ± 0.82	1.65 ± 1.19	0.719
After 48 wk	2.16 ± 1.34	1.81 ± 0.87	0.931
Reduction	-0.64 ± 1.02	0.19 ± 0.31	0.103
P (baseline vs. 48 wk)	0.099	0.359
Total cholesterol (mg/dl)
Before treatment	4.83 ± 1.09	4.30 ± 1.54	0.173
After 48 wk	4.82 ± 1.52	5.20 ± 0.99	0.581
Reduction	-0.23 ± 0.95	-1.02 ± 1.18	0.182
P (baseline vs. 48 wk)	0.822	0.045
HDL (mmol/L)
Before treatment	1.18 ± 0.21	1.10 ± 0.14	0.341
After 48 wk	1.43 ± 0.74	1.23 ± 0.31	0.977
Reduction	-0.23 ± 0.71	-0.09 ± 0.16	0.672
P (baseline vs. 48 wk)	0.430	0.225
LDL (mmol/L)
Before treatment	3.19 ± 0.91	3.20 ± 0.94	0.877
After 48 wk	3.15 ± 1.18	3.40 ± 0.71	0.428
Reduction	0.10 ± 0.94	-0.04 ± 0.9	0.791
P (baseline vs. 48 wk)	0.807	0.332

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.